Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Paxlovid  COVID-19 treatment studies for Paxlovid  C19 studies: Paxlovid  Paxlovid   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent: 
0 0.5 1 1.5 2+ Mortality 96% Improvement Relative Risk Mortality (b) 95% Hospitalization 88% Hospitalization (b) 89% c19early.com/pl Hammond et al. NCT04960202 Paxlovid RCT EARLY TREATMENT Favors paxlovid Favors control
Hammond, 2,085 patient paxlovid early treatment RCT: 96% lower mortality [p=0.0005] and 88% lower hospitalization [p<0.0001] https://c19p.org/hammond
copied to clipboard
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Hammond et al., New England Journal of Medicine, doi:10.1056/NEJMoa2118542, NCT04960202 (history)
16 Feb 2022    Source   PDF   Share   Tweet
EPIC-HR RCT, 1,039 higher risk patients treated with paxlovid (PF-07321332 + ritonavir) and 1,046 control patients, showing significantly lower mortality and hospitalization with treatment. NCT04960202 (history).
risk of death, 96.0% lower, RR 0.04, p < 0.001, treatment 0 of 1,039 (0.0%), control 12 of 1,046 (1.1%), NNT 87, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), within 5 days.
risk of death, 94.8% lower, RR 0.05, p = 0.002, treatment 0 of 697 (0.0%), control 9 of 682 (1.3%), NNT 76, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), within 3 days.
risk of hospitalization, 87.6% lower, RR 0.12, p < 0.001, treatment 8 of 1,039 (0.8%), control 65 of 1,046 (6.2%), NNT 18, within 5 days.
risk of hospitalization, 88.9% lower, RR 0.11, p < 0.001, treatment 5 of 697 (0.7%), control 44 of 682 (6.5%), NNT 17, within 3 days.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hammond et al., 16 Feb 2022, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries, peer-reviewed, 12 authors, average treatment delay 2.93 days, trial NCT04960202 (history).
All Studies   All Outcomes   Submit Updates or Corrections
This PaperPaxlovidAll
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit